Syed Naqvi

Assistant Professor

UAMS

Also affiliated: McLaren Regional Medical Center (2021); The University of Texas MD Anderson Cancer Center (2018–2020); University of Kentucky (2021–2023); University of Arkansas Medical Center (2024); Michigan State University (2021)

COM | Internal Med Hem-Onc

8 h-index 42 pubs 142 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Syed Naqvi is an Assistant Professor in the Department of Internal Medicine, Division of Hematology-Oncology at the University of Arkansas for Medical Sciences. His research focuses on palliative care, particularly concerning advanced non-small cell lung cancer patients. Naqvi has investigated the outcomes of embedded palliative care outpatient consults on symptom management and end-of-life care indicators. His work also examines the frequency of concomitant use of gabapentinoids and opioids for cancer-related pain, as well as the implications of opioid shortages on pain control for hospitalized cancer patients referred to palliative care. Additionally, Naqvi has explored factors associated with improved uncontrolled cancer pain without increasing opioid dosage and contributed to the development of a nomogram to predict the risk of non-medical opioid use in cancer patients. He has a current h-index of 8 with 27 total publications and 297 citations.

Metrics

h-index: 8
Publications: 42
Citations: 142

Positions

Assistant Professor publications 2024–2026

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (2025)

Blood DOI OpenAlex
Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (2025)

Blood DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
MM-1211: A 22-Year Snapshot of Demographic and Regional Disparities in Multiple Myeloma Patients with Renal Failure (1999–2020) (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex